TY - JOUR AU - Rokavec, Matjaz AU - Du, Yuyun AU - Hermeking, Heiko TI - Down-regulation of RBM47 due to diminished activation by forkhead box A1 (FOXA1) and silencing by CpG methylation is associated with epithelial-mesenchymal transition and metastasis of colorectal cancer. JO - Molecular biomedicine VL - 6 IS - 1 SN - 2662-8651 CY - Cham PB - Springer Nature Switzerland M1 - DKFZ-2025-02737 SP - 133 PY - 2025 AB - The gene encoding the RNA-binding motif protein 47 (RBM47) is highly expressed in epithelial cells and its down-regulation is characteristic for many types of cancer, among them colorectal cancer (CRC). However, the underlying mechanisms for this differential expression of RBM47 and its functional consequences during CRC progression have remained unknown. Here we found that RBM47 expression progressively decreases during CRC progression and is associated with poor prognosis and the metastatic CRC subtypes CMS4 and CRIS-B. In mice and humans RBM47 expression was highest in endoderm-derived tissues. The expression of forkhead box A1 (FOXA1), a transcription factor essential for the development of endoderm-derived epithelial tissues, showed a positive correlation with RBM47 expression in human tissues, as well as in primary CRCs and derived cell lines. Like RBM47, FOXA1 showed a down-regulation during CRC progression that is associated with poor prognosis and CMS4/CRIS-B. Ectopic FOXA1 induced RBM47 via directly binding to FOXA1 binding sites within the RBM47 promoter region. Up-regulation of RBM47 was necessary for FOXA1-mediated mesenchymal-to-epithelial transition (MET) and inhibition of CRC cell migration and invasion. RBM47 expression was silenced by CpG methylation in mesenchymal-like CRC cell lines. Moreover, epigenetic silencing of RBM47 in primary CRCs was associated with liver metastases. Therefore, the down-regulation of RBM47 is presumably initially mediated by loss of FOXA1 expression and subsequently fixed by CpG methylation of the RBM47 promoter. This down-regulation of RBM47 facilitates EMT and thereby promotes CRC metastasis. Finally, our results show that CpG hypermethylation of the RBM47 promoter represents a potential biomarker for metastatic CRC. KW - Humans KW - Colorectal Neoplasms: genetics KW - Colorectal Neoplasms: pathology KW - Colorectal Neoplasms: metabolism KW - Epithelial-Mesenchymal Transition: genetics KW - DNA Methylation: genetics KW - RNA-Binding Proteins: genetics KW - RNA-Binding Proteins: metabolism KW - Animals KW - Down-Regulation KW - Gene Expression Regulation, Neoplastic KW - CpG Islands: genetics KW - Hepatocyte Nuclear Factor 3-alpha: metabolism KW - Hepatocyte Nuclear Factor 3-alpha: genetics KW - Cell Line, Tumor KW - Gene Silencing KW - Mice KW - Neoplasm Metastasis KW - Promoter Regions, Genetic KW - Prognosis KW - Cell Movement: genetics KW - Female KW - Male KW - Colorectal cancer (Other) KW - DNA methylation (Other) KW - FOXA1 (Other) KW - Mesenchymal- epithelial transition/MET (Other) KW - Metastasis (Other) KW - RBM47 (Other) KW - RNA-Binding Proteins (NLM Chemicals) KW - Hepatocyte Nuclear Factor 3-alpha (NLM Chemicals) KW - FOXA1 protein, human (NLM Chemicals) LB - PUB:(DE-HGF)16 C6 - pmid:41335176 DO - DOI:10.1186/s43556-025-00382-4 UR - https://inrepo02.dkfz.de/record/306753 ER -